INTRODUCTION
The increasing antibiotic resistance is the main reason for Helicobacter pylori (H. pylori) treatment failure [1] . After an unsuccessful firstline regimen (usually triple or sequential/concomitant/ hybrid therapies), guidelines recommend a triple therapy with levo oxacin or a bismuth/ tetracycline/metronidazole quadruple regimen [2] . When a second-line treatment fails, the possible options are very limited [3] . In this case, Maastricht-IV Consensus advises a treatment guided by antimicrobial susceptibility testing, i.e. culture [2] . However, despite the fact that this technique may permit the achievement of good eradication rates [4] , culture is not feasible everywhere and di cult to perform even in expert hands. Moreover, the limited number of effective antibiotics against the bacterium narrows the eld of options. On the other hand, Italian guidelines [5] suggest a rifabutin based triple therapy as a third line. e possibility of using an empiric third-line regimen when culture is not available or most antibiotics have failed is essential, and rifabutin has been investigated in many studies, with a success rate ranging from 44 to 95% [6] . In a recent meta-analysis, the mean percentage of success of a rifabutin-based triple therapy (rifabutin, amoxicillin and a proton pump inhibitor -PPI) was 66% when used in third line [6] . Tetracycline is a class of antibiotics that is largely used in second and third line therapy [7] , usually in association with bismuth and metronidazole, the so called "quadruple therapy". However, in Italy the commercial package of tetracycline contains tablets with a dose of 250 mg. erefore, for an e ective treatment, the patient is requested to assume 8 pills/day of tetracycline in addition to the other drugs with a total number of 16 tablets/day for at least 10 days. It may be argued that relevant consequences on the compliance are very common. Minocycline belongs to the tetracycline class. It is used at a dose of 100 mg (one tablet) twice daily, and this could push the patient to a complete adherence to the therapeutic regimen.
erefore, herein we describe a preliminary experience with a novel quadruple regimen containing rifabutin, minocycline and bismuth (RMB) as a rescue therapy in patients who had failed at least two previous regimens, compared to a classical quadruple therapy which comprised minocycline, tinidazole and bismuth (MTB).
PATIENTS AND METHODS
Patients who failed a rst-line regimen (either prolonged triple or sequential therapy) and successively a levo oxacinbased triple therapy were considered for the study. Before starting the treatment, all eligible patients underwent a full blood count and evaluation of renal (creatinine, blood urea nitrogen) and hepatic function (transaminases, bilirubin, alkaline phosphatase and gamma-glutamyl transpeptidase). All subjects with cytopenia (de ned as white blood cells < 4,000/ μL, hemoglobin < 10g/dL and platelets < 150,000/μL), impaired renal function and liver cytolysis/cholestasis were excluded. All subjects had H. pylori infection diagnosed by the concordance of the urea breath test (UBT) and stool test antigen (ST). e diagnosis was con rmed by upper endoscopy with histology before starting the therapy. e patients were randomized 1:1 to the rifabutin-based quadruple therapy (RMB) or to the modi ed conventional quadruple therapy (MTB). Both treatments lasted 10 days.
The RMB eradication regimen was given as follows: e result of the eradication treatment was checked by UBT and ST 6 weeks a er its cessation, and therapy was considered successful only when both tests con rmed H. pylori negativity. When necessary (ulcer or low grade MALT lymphoma) a second endoscopy/histology was performed. At the 5th day and the end of therapy, the side e ects were investigated by a personal interview. e χ2 test or the Fisher's exact probability test were used, as appropriate, to compare the percentages and nominal variables. For continuous variables, di erences between the patients in the two treatment arms were compared using the Student t-test for unpaired samples. e eradication rates were expressed both as intention-to-treat (ITT) and per-protocol (PP) analysis, and 95% con dence interval (95% CI) was provided. e statistical analysis was performed using the statistical so ware GraphPad Prism version 5.00 for Windows, GraphPad So ware, San Diego California USA.
RESULTS
In the rst line, 22 patients (40.7%) had failed sequential regimen, while 32 (59.3%) a 10-day triple therapy. All patients had successively failed a second line levo oxacin-amoxicillin 10-day triple therapy.
In the RMB group, 21 patients eradicated the bacterium. Two subjects dropped out, so no data regarding their therapy results are available. e eradication rate was 77.7% (CI 62.0-93.4%) at ITT and 84.0% (CI 69.6-98.4%) at PP analysis.
In the MTB group, 14 patients eradicated H. pylori. We did not record any drop out. e eradication rate was 51.9% (CI 33.1-70.7%) at both PP and ITT analysis.
H. pylori related disorders and therapeutic outcome of enrolled patients are described in Table I .
No patient withdrew from the treatment for adverse events. Main drug-related side e ects were reported only in 3 subjects (5.6%): diarrhea in two cases (one in RMB and one in MTB) and severe asthenia in the other one (RMB). However, in both cases the treatment was not halted and in the rst case a probiotic supplementation was given.
DISCUSSION
H. pylori is a well-known cause of gastritis, peptic ulcer and malignant diseases of the stomach [8, 9] . Since its eradication is able to avoid the evolution of gastric lesions into severe gastric malignancies, such as adenocarcinoma or lymphoma, e ective eradication regimens are required. However, antibiotic resistances are a frequent cause of therapy failure; therefore, rescue therapies are of strong relevance. Rifabutin is an anti-tuberculosis agent used in patients a ected by acquired immune-de ciency syndrome. Its use in H. pylori eradication regimens is indicated today only for the rescue therapy given the low rates of antibiotic resistance [10] , the high economic costs and the potential severe side e ects, such as neutropenia or anemia [11] . A recent meta-analysis showed a mean percentage of success of a third-line rifabutin-based triple therapy (rifabutin, amoxicillin and a PPI) of 66% [6] .
e second antibiotic used in our regimens, minocycline, belongs to the tetracycline drug class, which has been associated with low rates of antibiotic resistance in Italy [12] . shows a disappointing e ectiveness (38.5%) [13] . However, the case of a multi-resistant H. pylori strain successfully treated with minocycline/amoxicillin/bismuth has been described [14] . Tetracycline has been employed in third line regimens, enclosed in classical bismuth-containing quadruple therapy, with results varying from 65% in a recent Spanish trial [15] to 36% in another study conducted in the year 2000 in the same country [16] .
e data of the present preliminary report demonstrated that the association minocycline/rifabutin has a satisfactory eradication rate (PP: 84%; ITT: 77.7%) when compared to previous studies using tetracycline or rifabutin alone. is e ect could be explained by two main reasons: i) two di erent antibiotics with low resistance rates were combined, and ii) these antibiotics had not been used in precedent eradication regimens in our patients. On the other hand, a conventional bismuth based quadruple therapy, although with minocycline instead of tetracycline, did not reach a satisfactory eradication rate (51.9%). e use of tinidazole, which was already employed in first line by some patients, could explain this result. Nevertheless, the di erent outcomes of the two regimens could not have been a ected by the previous tinidazole assumption, as clearly shown in Table I .
Based on this hypothesis, the association rifabutinminocycline could have a synergic action and fulfills its maximal potential therapeutic e ect when compared with other third line schemes. e possibility of the combination of these two drugs is secondary to the approval of local pharmaceutical agencies. Both drugs were approved by the Food and Drug Administration (FDA) [17] and by the European Medicines Agency (EMA), so they are available both in Europe and the United States [18] . Studies related to their use in Asian and African countries are also available [19] [20] [21] [22] .
Of relevance, H. pylori eradication was obtained in two patients with low grade MALT lymphoma.
In our study, no patient developed severe drug reactions. Possible explanations may be : i) the short duration of the treatment (rifabutin side e ects are common in a 14-day lasting regimen [23] or when the dose is 600mg/day for mycobacterial infection [24] ), and ii) the exclusion criteria that did not allow the enrolling of patients at high risk of severe reactions to both antibiotics.
Despite the encouraging results, this is a preliminary study and the present data come from a small-size group of subjects.
is last aspect is due to the rarity of multiple failures, since the patients were recruited during a period of one year. In conclusion, further investigations are required to con rm our results and to de nitively ascertain the e ectiveness and safety of the combination rifabutin-minocycline in H. pylori multi-resistant infection. 
